Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market
PORTLAND, Oregon, November 25, 2014 /PRNewswire/ --
Research Beam adds a report titled "Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market" that provides detailed information of the Critical Care Therapeutics in Major Developed Markets. The report is an excellent piece of study for investors who are looking towards the market.
GBI Research, the leading business intelligence provider, has released its latest research: "Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market", which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates.
The total value of the critical care market in the major developed markets was estimated at $1.8 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019. This growth is attributed to the recent approval of new factor concentrates in the US that are expected to witness increasing uptake in the forecast period. Factor concentrates are increasingly preferred due to their lower infection risks over older alternatives such as FFP and cryoprecipitate in critical care settings.
See Complete Report with TOC: http://www.researchbeam.com/critical-care-therapeutics-in-major-developed-to-2020-new-and-late-stage-four-factor-pccs-and-recombinant-products-to-drive-market
The US accounts for the largest share (41%) of the global critical care market and is expected to post high growth at a CAGR of 7.5% until 2020. KCentra, the first four-factor PCC in the US, and Tretten, the first recombinant FXIII concentrate, were approved in 2013 and are expected to witness good uptake in the forecast period. Two additional factor concentrates approved in the US in 2009 - RiaStap (human fibrinogen concentrate) and ATryn (recombinant AT concentrate) - are also expected to increase their uptake, which will contribute to market growth. With no new significant launches in the forecast period, the European market is estimated to witness much slower growth, with the UK at a CAGR of 3.0%, France at 2.5%, Germany and Spain both at 2.3%, and Italy at 2.0%
Scope
The report analyses treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in critical care in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report includes -
A brief introduction to the five major plasma-derived products in critical care and the indications that they are being used to treat, as well as disease overview, epidemiology, other treatment options, and treatment patterns
Analysis of major marketed products in critical care, covering product performance in terms of the safety and efficacy of recent approvals
A review of the critical care pipeline, including individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period
Multi-scenario forecasts of the critical care market over the 2013-2020 period in the eight major developed markets
Key drivers and restraints that have had and are expected to have a significant impact on the market
An overview of major licensing and co-development agreements that could affect growth trends
Reasons to buy
The report will enhance your decision-making capability by allowing you to -
Align your product portfolio to markets with high growth potential
Develop market entry and expansion strategies by identifying the regions and therapeutic segments poised for strong growth
Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the critical care drugs market
Develop key strategic initiatives based on an understanding of key focus areas and leading companies
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Request for Discount: http://www.researchbeam.com/critical-care-therapeutics-in-major-developed-to-2020-new-and-late-stage-four-factor-pccs-and-recombinant-products-to-drive-market/purchase-enquiry
Table of Contents
1 Table of Contents 7
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
3 Respiratory Diseases - Overview 12
3.1 Chronic Obstructive Pulmonary Disease - Epidemiology 12
4 Global Ventilators Market: Definitions 13
4.1 Adult/Pediatric Ventilators 13
4.2 Neonatal Ventilators 13
4.2.1 Transport Ventilators 13
5 Global Ventilators Market: Market Characterization 14
5.1 Global Ventilators Market, Revenue, 2006-2020 14
5.2 Ventilators Market, Global, Key Company Shares, 2013 15
5.3 Ventilators Market, Key Trends 16
5.3.1 Companies Focus on Development of Multimodal Ventilators to Prevent Lung Injury and Asynchrony 16
5.3.2 Advancements in Software, Facial Masks and Home Ventilation to Drive Growth of Ventilators 18
5.4 Market Dynamics 18
5.4.1 Market Drivers 19
5.4.2 Market Restraints 22
Similar Market Published Reports
ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations - GBI Research has released the pharma report, "ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations" Changes in diagnostic criteria have reduced the symptom threshold for diagnosis and finally bring the acceptance of adult ADHD to the clinical setting, enabling those previously unable to obtain a diagnosis to be diagnosed for ADHD treatment. In the case of adult ADHD, 4.1% of US adults are believed to suffer from ADHD, 41.3% of these cases are classified as severe and would be eligible for therapeutic intervention.
View Full Report at http://www.researchbeam.com/adhd-therapeutics-to-2020-broadened-diagnostic-criteria-and-growing-adult-prevalence-to-drive-growth-despite-patent-expirations-market
Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies - GBI Research, has released the pharma report -"Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies". The current Ovarian cancer therapeutics market is dominated by the use of generics - predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease (both first-line and recurrent). Initial treatment with platinum-based therapy is usually effective, with approximately 70% of patients entering remission. However, even with extended progression free-survival of 24 months, almost all patients relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies to extend the initial high rates of remission, and hopefully stimulate long-term remission in patients. As well as a gap for more effective treatment options in platinum-resistant or refractory patients.
View Full Report at http://www.researchbeam.com/sylentis-sa-product-pipeline-review-2014-market
Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use - GBI Research has released its pharmaceutical research, "Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use", which provides insights into three cardiovascular therapeutic indications in in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The report provides an in-depth analysis of the cardiovascular therapeutic indications, namely heart failure, myocardial infarction (MI), acute coronary syndrome (ACS). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three cardiovascular indications.
About Us
We have a large database of quality and precise market research reports that will be very beneficial for your organization. Reports that we sell our authentic in nature and from reputed publishers, hence it can definitely help you with your growth opportunities.
In order to survive the fierce competition and locate different avenues, one must be privy to high end and quality market information. So, we try and provide you with latest market information by getting high market research reports from our clients.
We have business relations with numerous clients of different verticals. Hence, we bring to you market research reports of various fields and carter to number of organizations. This is the spot on place for all your market research needs.
We are home to a very proactive and energetic team who strives to solve user queries as soon as possible. They will also help you to know about latest market trends and practices.
Research Beam will always make sure to bring most ethical and high quality reports. We value your relationship with us and look forward for a long term relation.
Contact Us:
Deep Joshi
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
Direct: +1 (617) 674-4143
Toll Free: +1 (855) 711-1555
Fax: +1 (855) 550-5975
Mail: sales@researchbeam.com
Blog: researchbeam.blogspot.com
Share this article